Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 2/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.59 |
| ▸ | BCL2 | P10415 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27013412 | 0.91 | AKT1 (0.83) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL29808704 | 0.91 | AKT1 (0.83) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL1231403 | 0.89 | PDE4D (1.00) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL29808504 | 0.89 | PDE4D (1.00) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL20045159 | 0.88 | DYRK1A (0.84) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL3192507 | 0.87 | PDE5A (0.83) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL20954090 | 0.87 | PDE5A (0.83) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL4227433 | 0.85 | PDE5A (0.80) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL27013490 | 0.85 | AKT1 (0.73) | AKT1PDE5AESR1PDE4DESR2 | |
| SCHEMBL30725644 | 0.85 | AKT1 (0.73) | AKT1PDE5AESR1PDE4DESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326734-B2 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | KLK5, KLK4, KLK6 | AKT1 2779/4885PDE5A 2937/4885ESR1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.